ClinicalTrials.gg
CompletedNCT00783042Updated Jun 30, 2009

Exploratory Study of Coronary Flow Reserve Measurements, a Non-Invasive Method for Coronary Function Measurements

An Early Phase 1 interventional study of Rosuvastatin and Placebo in Atherosclerosis and Inflammatory Activity in Coronary Arteries, sponsored by AstraZeneca. Completed at 1 site in Sweden. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-06-30.

Sponsored by AstraZeneca · Early Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 25 studies testing rosuvastatin in Atherosclerosis — 1 open to participants now, 2 under way, 1 of them phase 3. rosuvastatin · Atherosclerosis.

Planned enrollment
12th of 24
80 · median 77
Started
2008
with 2 others
Phase 1
3 of 25
none open now
Registered
9th of 25
by date
Lead sponsor
5 of 25
AstraZeneca

Among the 25 studies testing rosuvastatin in Atherosclerosis, this one is the 12th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2008, is one of 3 in phase 1, and was the 9th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

1 of the 25 studies testing rosuvastatin in Atherosclerosis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing rosuvastatin in Atherosclerosis, or all of them as a file.
02

Study summary

The aim of this study is to investigate whether the non-invasive ultrasound method for assessment of coronary blood flow, transthoracic Doppler echocardiography-coronary flow reserve (TTDE-CFR), can be used to measure drug effects.

03

Conditions studied

  • Atherosclerosis
  • Inflammatory Activity in Coronary Arteries

Browse trials for

Keywords

  • TTDE-CFR
  • coronary artery function
  • cardiovascular biomarkers
  • rosuvastatin
  • Crestor
04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males aged 45-75 years or females aged 60-75 years inclusive
  • Carotid and/or femoral atherosclerotic plaque, as assessed by carotid ultrasound examination within the last 5 years
  • Abnormal concentrations of lipids or lipoproteins in the blood
  • Provision of signed

Exclusion criteria

Exclusion Criteria:

  • Treatment with statins or other lipid-lowering drugs, e.g. fibrates, nicotinic acid, cholesterol absorption inhibitor, within the last 6 months before randomisation
  • Current smoking or snuff tobacco use
  • Major CV event (myocardial infarction (MI), stroke/ transitory ischemic attack (), Acute Coronary Syndrome (ACS), revascularisation) within the last 6 months before randomisation
  • Symptomatic carotid stenosis, atrioventricular (AV) block, -prolongation, atrial fibrillation, sinus node disease (such as sick sinus syndrome or symptomatic bradycardia), (COPD) or asthma
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    1

    Drug: Rosuvastatin

  • Placebo comparator
    2

    Drug: Placebo

Interventions

  • 40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).

    Also known as: Crestor

  • DrugPlacebo

    Tablet, oral, once daily for 1 month (double blind)

06

What researchers measure

Primary outcomes

  1. Change in CFR peak velocity within rosuvastatin group after 1 month of treatment compared to baseline

    Time frame: Baseline and after 1 month of treatment

  2. Comparison of treatment effects on CFR peak velocities between groups after 1 month of treatment

    Time frame: Baseline and after 1 month of treatment

Secondary outcomes

  1. Changes in CFR peak velocity within the rosuvastatin group after 3 months compared to baseline and to 1 month

    Time frame: Bseline, after 1 month and after 3 months of treatment

  2. Changes in other CFR parameters after one month rosuvastatin or placebo treatment; comparisons within groups and between groups

    Time frame: Baseline and after 1 month of treatment

  3. Changes in plasma lipids, lipoproteins and other cardiovascular biomarkers after 1 month of treatment with rosuvastatin or placebo; comparisons within groups and between groups

    Time frame: Baseline and after 1 month of treatment

07

Study locations

1 site
  • Research Site
    Goteborg, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008 and a completion of May 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2008
First posted
Oct 31, 2008
Start
Oct 2008
CompletionActual
May 2009
Last update
Jun 30, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00783042
Lead sponsor
AstraZeneca
First posted
Oct 31, 2008
Start date
Oct 2008
Completion
May 2009
Last update
Jun 30, 2009

Study contacts

Björn Fagerberg, MD, Professor
principal investigator · Wallenberg LaboratorySahlgrenska University Hospital, S-413 45 Göteborg
Maria Leonsson-Zachrissson, MD
study chair · AstraZeneca R&D Mölndal

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion